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Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk. The Reduction of Car-
diovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) demonstrated that the purified,
stable ethyl ester of eicosapentaenoic acid, icosapent ethyl (IPE), added to statins reduced CVD events by
25% (p < 0.001), leading to an expanded indication in the USA. IPE is now approved as an adjunct to
maximally tolerated statins to reduce CVD event risk in adults with triglyceride (TG) levels ≥150 mg/dl
and either established CVD or diabetes mellitus plus ≥2 additional CVD risk factors. The new indication
allows co-administration of IPE for elevated TG levels with statin treatment, enabling effective residual
risk reduction in a broader at-risk population beyond what can be achieved with intensive low-density
lipoprotein cholesterol control alone.
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Atherosclerotic cardiovascular disease (ASCVD) remains the most common cause of morbidity and mortality in the
USA and globally [1–5]. Hypertriglyceridemia is associated with increased ASCVD risk, independent of low-density
lipoprotein cholesterol (LDL-C) control [6]. Triglyceride (TG)-lowering therapies such as niacin, fibrates and mixed
omega-3 fatty acids have not demonstrated cardiovascular disease (CVD) risk reduction on top of contemporary
medical therapy including statins [7].
Icosapent ethyl (IPE), a highly purified, stable ethyl ester of eicosapentaenoic acid (EPA), was originally approved
by the US FDA as an adjunct to diet for treatment of adults with severe (≥500 mg/dl) hypertriglyceridemia [8].
Addition of 4 g/day of IPE to statin-controlled patients with elevated TG levels (≥150 mg/dl) and high risk for
ASCVD events resulted in reduction of ASCVD events compared with statin treatment alone in the Reduction of
Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) [9]. On the basis of the REDUCE-IT
findings, the FDA recently approved an expanded CVD risk reduction indication for IPE [8].
This narrative review will discuss the role of TG and TG-lowering treatments in ASCVD risk reduction,
summarize the results of the REDUCE-IT trial and highlight the clinical and economic implications of the FDA’s
recent decision to approve IPE as the first TG-lowering treatment indicated for ASCVD residual risk reduction.
Overview of hypertriglyceridemia: clinical & economic impact
Biology, epidemiology & clinical burden of hypertriglyceridemia
Increases in TG-rich lipoproteins (TRL), such as chylomicrons and very-low-density lipoproteins (VLDL), re-
sult in hypertriglyceridemia [10]. Primary lipoprotein phenotypes characterized by hypertriglyceridemia, as defined
by Fredrickson, Levy and Lees, are summarized in Table 1 [11]. Common underlying primary causes of hyper-
triglyceridemia include familial hypertriglyceridemia, which is caused by excess hepatic VLDL production and
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Table 1. Frederickson-Levy phenotypes characterized by hypertriglyceridemia†.
Frederickson-Levy phenotype Main features Diagnostic criteria
Type I Chylomicron excess TG:TC ratio 10 and VLDL-C 90th percentile
Type III Remnant lipoprotein cholesterol excess VLDL-C:TG ratio 0.3, TG 130 mg/dl and LDL-C 90th percentile
Type IV VLDL-C excess VLDL-C 90th percentile, LDL-C 90th percentile and VLDL-C:TG ratio 0.3
Type V Chylomicron and VLDL-C excess TG:TC ratio 10 and VLDL-C 90th percentile
†Not listed within the table are phenotypes primarily characterized by high LDL-C: type IIa (main feature is LDL-C excess; diagnostic criteria are LDL-C 90th percentile, VLDL-C
90th percentile and VLDL-C:TG ratio 0.3) and type IIb (main features are LDL-C and VLDL-C excess; diagnostic criteria are LDL-C, VLDL-C 90th percentile and VLDL-C:TG ratio
0.3).
LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; VLDL-C: Very-low-density lipoprotein cholesterol.
Reproduced from [11], CC BY-NC-SA.
Table 2. Genetic polymorphisms underlying hypertriglyceridemia.
Genetic target polymorphism Pathogenesis Typical lipid/lipoprotein profile Ref.
Apo C2 deficiency Absence of needed cofactor, apo C2, leads to increased
chylomicrons
Homozygotes TG:cholesterol ratio
10:1; TG 1000 mg/dl; increased
chylomicrons
Obligate heterozygotes with normal
TG despite apo C2 levels ∼30–50% of
normal
[10,12]
Apo C3 Deficiency in apo C3 associated with low TG levels; gain of function
mutation associated with enhanced hepatic de novo lipogenesis
[13,14]
Angiopoietin-like protein 3 and 4 Loss of function mutations associated with lower TG levels [13,15]
Apo A5 deficiency Mutations in the APOA5 gene, which lead to truncated apo A5
devoid of lipid-binding domains located in the carboxy-terminal
end of the protein
Homozygotes: TG:cholesterol ratio
10:1; TG 1000 mg/dl; increased
chylomicrons
[10,12,16]
Lipoprotein lipase deficiency Very low or undetectable levels of lipoprotein lipase lead to
increased chylomicrons; circulating inhibitor to lipoprotein lipase
has been reported
Homozygotes: TG:cholesterol ratio 10:1;
TG 1000 mg/dl; increased
chylomicrons
[10,12]
Hepatic lipase deficiency Relatively rare LIPC mutations lead to loss in circulating hepatic
lipase activity (due to impaired secretion or inactive enzyme)






Mutations in GPIHBP1 may reduce binding to LPL and hydrolysis of
chylomicron TGs
TG:cholesterol ratio 7:1; TG
500 mg/dl; increased chylomicrons
partially responsive to low-fat diet
[10,12]
Apo: Apolipoprotein; HDL: High-density lipoprotein; LPL: Lipoprotein lipase; TG: Triglycerides; VLDL: Very-low-density lipoprotein.
Source: American Heart Association, Inc. [10]
is characterized by normal cholesterol levels, and familial combined hyperlipidemia, which is caused by poorly
defined polygenic influences on lipoprotein metabolism [12]. Genetic polymorphisms that may impact TG levels
are summarized in Table 2 [10,12–17]. Secondary causes of hypertriglyceridemia include diabetes mellitus, central
obesity, dietary excess, hypothyroidism and chronic kidney disease [12]. One quarter of US adults, and up to a
third of those on statins, have elevated TG levels (≥150 mg/dl), likely due to contributions of obesity and other
metabolic diseases [10,18–21].
Hypertriglyceridemia is associated with increased ASCVD risk, independent of LDL-C control [6,21–27]. For
example, a recent claims-based analysis of over 20,000 statin-treated patients with diabetes and/or ASCVD found
that, despite having generally controlled LDL-C, patients in the high-TG cohort (TG levels 200–499 mg/dl)
had a 34.9% higher risk of major CVD events than a propensity-matched cohort with TG levels <150 mg/dl
and high-density lipoprotein cholesterol (HDL-C) levels >40 mg/dl [6]. A meta-analysis of 61 prospective clinical
trials that assessed the association between baseline blood TG levels with CVD mortality (33 studies) or with
all-cause mortality (38 studies) reported that, compared with TG levels 90–149 mg/dl, TG levels 150–199 mg/dl
were associated with a 15 and 9% increased risk of CVD mortality and all-cause mortality, respectively; TG levels
≥200 mg/dl were associated with even greater increases in risk of 25 and 20%, respectively [28]. Consistent with
these clinical findings, genetic data, including Mendelian randomization studies, support an association between
elevated TG levels and ASCVD risk [29–31].
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Economic burden
The economic consequences of residual CVD risk associated with hypertriglyceridemia are substantial [6,22,25,26].
An analysis based on National Health and Nutrition Examination Survey (NHANES) 2007–2014 surveys and
insurance claims data for a sample of US adults aged ≥45 years found that TG levels ≥150 mg/dl translated to a
projected overall additional cost burden of US$10.7 billion annually compared with TG levels <150 mg/dl (95%
CI, $6.8–14.6 billion) [22].
Current role of TG-lowering drugs in reducing ASCVD event risk
Overview of niacin studies
Clinical trials assessing the use of niacin in addition to statin treatment for CVD prevention are summarized in
Table 3 [32–38]. Neither the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyc-
erides: Impact on Global Health Outcomes (AIM-HIGH) nor the Heart Protection Study 2–Treatment of HDL
to Reduce the Incidence of Vascular Events (HPS2-THRIVE) achieved its primary cardiovascular end point [32,33].
Findings in subgroup analyses of patients with higher TG levels were inconsistent. While a trend toward CVD event
risk reduction for niacin versus placebo was found in a post hoc analysis of the high-TG/low-HDL-C subgroup
of AIM-HIGH [34], no difference between treatment groups was found among high-TG/low-HDL-C patients in
HPS2-THRIVE [33].
Overview of fibrate studies
Details of clinical trials evaluating fibrates for prevention of CVD events are summarized in Table 3. An early
study of fibrate monotherapy in the pre-statin era, the Veterans Affairs Cooperative Studies Program High-Density
Lipoprotein Cholesterol Intervention Trial (VA-HIT), found that in men with a documented history of coronary
heart disease and low HDL-C levels (≤40 mg/dl), gemfibrozil reduced the rate of the primary end point (death
from coronary heart disease or nonfatal myocardial infarction [MI]) versus placebo by 22% (95% CI: 7–35%; p
= 0.006) [35]. However, the subsequent literature has suggested that gemfibrozil should not be combined with statins
since inhibition of statin glucuronidation may increase serum statin levels, leading to increased myopathy risk [39].
More recent pharmacokinetic data suggest there are differences in the severity of interactions between gemfibrozil
and different statins. Interactions between simvastatin, lovastatin and pravastatin are considered moderate, while
interactions between gemfibrozil and rosuvastatin, atorvastatin and pitavastatin are considered minor [40]. These
findings have prompted the American Heart Association (AHA) to recommend that combination therapy with
gemfibrozil and rosuvastatin, atorvastatin, or pitavastatin may be considered if clinically indicated; nevertheless,
statin-fibrate combination therapy with fenofibrate is preferred in those guidelines [40]. However, the American
Diabetes Association guidelines note that statins should generally not be combined with either fibrates or niacin
as a Level A recommendation [41]. Thus, the CVD risk reduction findings with gemfibrozil are not as relevant
in the contemporary statin era. Fenofibrate has been shown to improve activation of ezetimibe by increasing its
glucuronidation [42]. However, large, randomized, controlled studies of other fibrates (bezafibrate and fenofibrate)
have failed to achieve their primary cardiovascular end points regardless of whether these fibrates were used as
monotherapy [36,37] or in combination with statins [38]. Subgroup analyses from these studies have suggested
fibrates may lower CVD event risk in patients with higher TG levels, a notion that still needs to be proven
prospectively [36–38].
Thus, although niacin and fibrates have TG-lowering effects, large outcomes trials evaluating these treatments as
add-on therapy to statins have failed to demonstrate significant ASCVD event risk reduction [32,33,38]. An ongoing
clinical trial utilizing a newer fibrate, the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides
in Patients With Diabetes (PROMINENT; NCT03071692), is targeting patients with high TG levels (fasting,
200–<500 mg/dl) and Type 2 diabetes taking moderate- to high-intensity statin therapy or meeting specified
LDL-C criteria (≤70 mg/dl within 12 months prior to enrollment or ≤100 mg/dl if statin-intolerant) [43]. Results
of this study will help clarify the role of a newer fibrate in addressing residual ASCVD event risk.
Role of omega-3 fatty acids in reducing ASCVD event risk
Omega-3 fatty acids have been demonstrated to be efficacious in TG lowering [44,45], and may exert pleiotropic
effects beyond TG lowering, which could contribute to reduction of residual ASCVD event risk [46,47]. EPA and
docosahexaenoic acid (DHA) have distinct biologic functions and electrophysiologic properties [48–50]. While both
are incorporated in membrane phospholipids in the sn-2 position, EPA appears to have more potent antioxidant
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Table 3. Randomized controlled cardiovascular outcomes trials of niacin and fibrates.
Trial Treatment and patient population Findings Ref.
AIM-HIGH • Niacin + statin vs placebo + statin in 3414 adults
• Age ≥45 years with established ASCVD and atherogenic
dyslipidemia
• HDL-C 40 mg/dl for men and 50 mg/dl for women
• TG 150–400 mg/dl
• LDL-C 180 mg/dl
Niacin + statin did not achieve the primary end point (composite of
the first event of death from coronary heart disease, nonfatal MI,
ischemic stroke, hospitalization [for 23 h] for an acute coronary
syndrome, or symptom-driven coronary or cerebral revascularization)
[32]
TG-related subgroup analysis
In patients with baseline TG ≥198 mg/dl and HDL-C 33 mg/dl, CV
risk reduction with niacin was suggested but not significant (HR, 0.74;
p = 0.073); the trend toward risk reduction with niacin was more
pronounced in patients with TG ≥200 mg/dl and HDL-C 32 mg/dl
(HR: 0.64; p = 0.032)
[34]
HPS2-THRIVE • Niacin + laropiprant added to statin vs placebo added to
statin in 25,673 adults
• Ages 50–80 years with a history of MI, cerebrovascular
disease, PAD, or diabetes with evidence of symptomatic
coronary disease
Niacin + laropiprant added to statin did not achieve the primary end
point (composite of major vascular events: nonfatal MI, death from




No significant difference in major vascular events was found between
niacin + laropiprant and placebo in the subgroup of patients with TG
151 mg/dl and low HDL-C (40 mg/dl in men, 51 mg/dl in women)
VA-HIT • Gemfibrozil vs placebo in 2531 men with a documented
history of coronary heart disease
• HDL-C ≤40 mg/dl, LDL-C ≤140 mg/dl and TG ≤300 mg/dl
Gemfibrozil reduced the rate of the primary end point (death from
coronary heart disease or nonfatal MI) vs placebo by 22% (95% CI:
7–35%; p = 0.006)
[35]
TG-related subgroup analysis
Gemfibrozil was associated with relative risk reduction in death from
coronary heart disease, nonfatal MI and confirmed stroke: 28% (95%
CI: 8–44) in patients with TG 151 mg/dl and 27% (95% CI: 75–42%)
in patients with TG ≥151 mg/dl (p = 0.01 for both)
FIELD • Fenofibrate vs placebo in 9795 non-statin–treated adults
• Ages 50–75 years with type 2 diabetes and total cholesterol
116.0–251.4 mg/dl and TG 88.6–442.9 mg/dl
• Not treated with lipid-modifying treatment at study entry
Fenofibrate did not achieve the primary end point (first occurrence of
nonfatal MI or death from coronary heart disease); however,
fenofibrate did reduce total CVD events (CVD death, MI, stroke and
coronary or carotid revascularization) vs placebo by 11% (HR: 0.89;
95% CI: 0.80–0.99; p = 0.035)
[36]
TG-related subgroup analysis
In patients with baseline TG ≥150.6 mg/dl, there was a trend (p
= 0.07) toward fenofibrate reducing total CVD events
BIP • Bezafibrate 400 mg vs placebo in adults aged 45–74 years
with history of MI ≥6 months but 5 years before study
enrollment and/or stable angina pectoris
• Lipid entry criteria included total cholesterol 180–250 mg/dl;
LDL-C ≤180 mg/dl (≤160 mg/dl if aged 50 years); HDL-C
≤45 mg/dl, and TG ≤300 mg/dl
Bezafibrate did not achieve the primary end point (fatal MI, nonfatal
MI, or sudden death [occurring within 24 h of onset of symptoms])
[37]
TG-related subgroup analysis
In patients with baseline TG ≥200 mg/dl, the adjusted relative risk for
primary end points associated with bezafibrate was 0.57 (95% CI:
0.35–0.93)
ACCORD • Fenofibrate + statin vs placebo + statin in 5518 patients with
type 2 diabetes
• Ages 40–79 years if clinical CVD, or ages 55–79 years if
subclinical CVD or ≥2 additional risk factors
• Lipid criteria: LDL-C 60–180 mg/dl; TG 750 mg/dl if no lipid
treatment or 400 mg/dl if on lipid treatment; low HDL-C
(55 mg/dl for women and black patients; 50 mg/dl for other
groups)
Fenofibrate + statin did not achieve primary end point (first
occurrence of major cardiovascular event, including nonfatal MI,
nonfatal stroke or death from cardiovascular causes)
[38]
TG-related subgroup analysis
In patients with TG ≥204 mg/dl and HDL-C ≤34 mg/dl, the primary
outcome rate was 12.4% for fenofibrate + statin vs 17.3% for
placebo + statin (nonsignificant suggestion of heterogeneity; p
= 0.057)
ACCORD: Action to Control Cardiovascular Risk in Diabetes; ACS: Acute coronary syndrome; AIM-HIGH: Atherothrombosis Intervention in Metabolic Syndrome with Low
HDL/High Triglycerides: Impact on Global Health Outcomes; ASCVD: Atherosclerotic cardiovascular disease; BIP: Bezafibrate Infarction Prevention; CVD: Cardiovascular disease;
FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; HPS2-THRIVE: Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events; HR: Hazard
ratio; MI: Myocardial infarction; PAD: Peripheral artery disease; VA-HIT: Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial.
effects [50,51], preserves membrane structure and maintains normal distribution of membrane cholesterol, inhibits
formation of cholesterol crystals, and positively influences the signal transduction pathways related to inflammation
and vasodilation [51]. DHA may be neuroprotective [52,53], has lipid-disordering effects that reduce antioxidant
activity, may increase membrane fluidity and promote changes in lipid domains [51], and has possible anti-arrhythmic
effects due to ion channel modulation [54]. Differential effects of omega-3 fatty acids on LDL-C have also been
observed: EPA appears to have a minimal or neutral effect, while DHA has been associated with increased LDL-C
levels, though the clinical consequences of this remain uncertain, particularly in subjects taking statins [44,45].
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Table 4. Cardiovascular outcomes trials of mixed omega-3 fatty acids.
Trial Treatment and patient population† Primary finding Ref.
GISSI Prevenzione DHA + EPA (1 g/day) vs vitamin E vs DHA + EPA with
vitamin E vs placebo in 11,324 patients within 3 months
post-MI
DHA + EPA significantly reduced the co-primary composite end
points vs placebo over 3.5 years: all-cause death, nonfatal MI and
nonfatal stroke was reduced by 15% (95% CI: 2–26%; p = 0.023)
and CV death, nonfatal MI and nonfatal stroke was reduced by
20% (95% CI: 5–32%; p = 0.008)
[55]
GISSI Heart Failure DHA + EPA (1 g/day) vs placebo in 7046 patients with
clinical evidence of heart failure (those with LVEF 40% had
to have had at least one hospital admission for heart failure
in the prior year); unless contraindicated, patients were also
randomly assigned rosuvastatin 10 mg or placebo
DHA + EPA produced a moderate reduction vs placebo in the
coprimary end points over 3.9 years: reduction in all-cause
mortality risk was 1.8% (95% CI: 0.3–3.9%) and reduction in
mortality or hospitalization for cardiovascular causes risk was 2.3%
(95% CI: 0–4.6%)
[62]
OMEGA DHA + EPA (∼1 g/day) vs placebo in 3851 patients aged
≥18 years and admitted to the hospital for acute MI
DHA + EPA did not achieve the primary end point of sudden
cardiac death (unexpected death from heart disease within 1 h for
first symptoms or unwitnessed overnight and/or sudden cardiac
arrest within 1 h of first symptoms with initially successful
cardiopulmonary resuscitation and subsequent death during the
hospital stay within 3 weeks)
[56]
Alpha Omega DHA + EPA (376 mg/day in a margarine) vs placebo in 4837
adults aged 60–80 years who had MI up to 10 years before
randomization
DHA + EPA did not achieve the primary end point (major
cardiovascular events: fatal and nonfatal cardiovascular events and
the cardiac interventions percutaneous coronary intervention and
coronary artery bypass grafting)
[58]
ORIGIN DHA + EPA (1 g/day) vs placebo in 12,536 adults aged
≥50 years with diabetes/dysglycemia and additional CVD
risk factors





DHA + EPA (1 g/day) vs placebo in 12,513 adults at high risk
for CVD (multiple risk factors), clinical evidence for ASCVD,
but no prior MI
DHA + EPA did not achieve the primary composite end point (time
to death from cardiovascular causes or hospital admission for
cardiovascular causes)
[59]
ASCEND DHA + EPA (1 g/day) in 15,480 adults aged ≥40 years with
diabetes but no evidence of CVD
DHA + EPA did not achieve the primary composite end point
(nonfatal MI or stroke [excluding confirmed intracranial
hemorrhage], transient ischemic attack, or vascular death
excluding intracranial hemorrhage)
[60]
VITAL DHA + EPA (1 g/day) and vitamin D vs placebo in 25,871
men aged ≥50 years and women aged ≥55 years
DHA + EPA did not achieve the primary end point (major
cardiovascular events [composite of MI, stroke and death from
cardiovascular causes] and invasive cancer of any type)
[61]
†Baseline statin use varied widely among these studies: 5% in GISSI-Prevenzione, 35% in VITAL, 41% in risk and prevention, 54% in ORIGIN, 75% in ASCEND, 86% in Alpha
Omega and 94% (at discharge) in OMEGA.
ASCEND: A Study of Cardiovascular Events in Diabetes; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; GISSI: Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto miocardico; HR: Hazard ratio; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; ORIGIN: Outcome Reduction with an Initial Glargine Intervention;
VITAL, Vitamin D and Omega-3 Trial.
Overview of mixed omega-3 fatty acid cardiovascular outcomes studies
Clinical trials assessing the impact of mixed omega-3 fatty acids (EPA + DHA) on cardiovascular outcomes have
not consistently demonstrated CVD event risk reduction (Table 4) [55–62]. An early open-label clinical trial, Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI-Prevenzione), found that mixed omega-3
fatty acids (EPA + DHA; <1 g/day) significantly reduced risk of death, nonfatal MI and nonfatal stroke by 15%
(95% CI: 2–26%; p = 0.023) and cardiovascular death, nonfatal MI and nonfatal stroke by 20% (95% CI: 5–32%; p
= 0.008) over 3.5 years in patients who had recently had an MI [55]. However, results of GISSI-Prevenzione may not
be generalizable to contemporary patient populations; baseline rates of revascularization and use of statin treatment
were both <6% [55], far below the current standard of care for a population with established ASCVD [63,64]. With
the exception of the GISSI-Heart Failure study, which reported modest risk reduction in a population with low
statin use [62], subsequent large, high-profile studies of mixed omega-3 fatty acids failed to demonstrate CVD event
risk reduction, whether in patients with established ASCVD [56,58] or at risk for ASCVD [57,59].
In recent years, two large-scale outcomes studies of low-dose (1 g fish oil/day as DHA 380 mg + EPA 460 mg)
prescription mixed omega-3 fatty acids failed to achieve their primary cardiovascular end points [60,61]. In A Study
of Cardiovascular Events in Diabetes (ASCEND), there was no difference in the occurrence of vascular events
between daily mixed omega-3 fatty acids and placebo over >7 years of follow-up in patients with diabetes and no
known baseline CVD [60]. Likewise, in the Vitamin D and Omega-3 Trial (VITAL), neither daily mixed omega-3
fatty acids nor vitamin D3 resulted in a significantly lower incidence of major cardiovascular events compared with
placebo over more than 5 years of follow-up in a primary prevention population [61].
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Factors leading to inconsistent findings in mixed omega-3 fatty acid studies may include heterogeneity of mixed
omega-3 products, relatively low doses used (∼1 g/daily), as well as differences in study populations, baseline TG
levels and baseline statin use [65,66].
In January 2020, another highly anticipated mixed omega-3 fatty acid trial, the Outcomes Study to Assess
Statin Residual Risk Reduction With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia
(STRENGTH), which investigated a prescription-strength dose (4 g/day) of a free fatty acid EPA + DHA mixture,
was discontinued early [67,68]. An independent Data Monitoring Committee recommended stopping the trial based
on preliminary data that showed the EPA + DHA mixture had a ’low likelihood’ of benefiting patients with mixed
dyslipidemia and an increased risk of CVD [69].
Early CV outcomes study of EPA alone
An open-label clinical trial of EPA alone, the Japan EPA Lipid Intervention Study (JELIS), found a 19% reduction
in ASCVD events among 18,645 Japanese patients treated with moderate-dose EPA (1.8 g daily) added to low-dose
statin therapy compared with placebo (statin only) (hazard ratio [HR], 0.81; 95% CI: 0.69–0.95; p = 0.011) [70].
However, the results from JELIS should be taken with some caution. Unlike REDUCE-IT, which will be discussed
in the next section, JELIS did not specifically enroll patients with elevated TG levels. Statin intensity was low in
JELIS, with the vast majority of patients (90%) on simvastatin 5 mg or pravastatin 10 mg [70]. These doses were
appropriate for the population studied but may not be generalizable to other populations. The mean attained
LDL-C level in JELIS was approximately 136 mg/dl [70], in contrast to a median attained LDL-C level of 77 mg/dl
in REDUCE-IT [9].
REDUCE-IT
Cardiovascular risk reduction with IPE
REDUCE-IT was the first prospective, placebo-controlled, randomized cardiovascular outcomes trial of IPE
4 g/day (2 g twice daily) in statin-controlled patients with elevated TG levels and established ASCVD or high
risk for ASCVD (i.e., diabetes and at least one additional CV risk factor) [9]. The primary efficacy end point (a
composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina)
occurred in 17.2% of patients in the IPE versus 22% of patients in the placebo group (HR: 0.75; 95% CI:
0.68–0.83; p < 0.001) [9]. Thus, compared with placebo, IPE significantly reduced important ASCVD events by
25% (Figure 1A). The key secondary end point (a composite of cardiovascular death, nonfatal MI, or nonfatal
stroke) occurred in 11.2% of patients in the IPE group versus 14.8% of patients in the placebo group (HR: 0.74;
95% CI: 0.65–0.83; p < 0.001). The numbers needed to treat (NNT) to prevent one primary end point or one
key secondary end point event were 21 and 28, respectively, over a median 4.9-year follow-up. In addition, the
relative risk of the total (first and subsequent) primary composite end point was significantly reduced by 30%
in the IPE versus placebo group (61 vs 89 events per 1000 patient-years; rate ratio: 0.70; 95% CI: 0.62–0.78; p
< 0.001; Figure 1B) [71]. The IPE group had significantly lower relative risks of individual cardiovascular end points
compared with placebo, including a 20% reduction in death due to cardiovascular causes (HR: 0.80; 95% CI:
0.66–0.98), 31% reduction in MI (HR: 0.69; 95% CI: 0.58–0.81), 28% reduction in stroke (HR: 0.72; 95% CI:
0.55–0.93) and 31% reduction in sudden cardiac death (HR: 0.69; 95% CI: 0.50–0.96) [9]. In the US subgroup
(n = 3146), the primary composite end point rate was 18.2% in the IPE group versus 24.7% in the placebo group
(HR: 0.69; 95% CI: 0.59–0.80), corresponding to a NNT of 15. The rate of the key secondary end point was
12.1% in the IPE group versus 16.6% in the placebo group (HR: 0.69; 95% CI: 0.57–0.83), corresponding to a
NNT of 22 [72].
TG levels in REDUCE-IT
IPE treatment achieved the primary or key secondary efficacy end points in REDUCE-IT independent of baseline
TG levels; additionally, CVD event risk reduction with IPE was not affected by whether TG levels attained at 1 year
after randomization were ≥150 or <150 mg/dl [9]. Although study inclusion required screening TG levels ≥135
to <500 mg/dl, baseline TG levels (defined as the average of screening and randomization visit TG levels) ranged
from 81 to 1401 mg/dl [73]. An analysis by TG tertiles across this wide range of baseline TG levels found that IPE
significantly reduced the risk of first and total occurrence of the primary composite end point versus placebo in all
TG tertiles (TG ≥81–≤190, >190–≤250 and >250–≤1401 mg/dl), with no heterogeneity in the relative risk
reduction between these groups [73]. For first occurrence of the primary composite end point, the HRs (95% CI;
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Key secondary composite endpoint
Placebo: total events
Icosapent ethyl: total events
Placebo: total events
Icosapent ethyl: total events
Figure 1. REDUCE-IT primary end point. (A) Time to first primary composite end point event [9]. (B) Total (first and
subsequent) primary composite end point events [71].
*The number of patients at risk for recurrent events.
Reproduced with permission from Bhatt et al. [9,71]. CC BY-NC-ND 4.0.
p-value) for the lowest to highest TG tertiles were 0.79 (0.66–0.94; p = 0.007), 0.80 (0.68–0.95; p = 0.012) and
0.68 (0.57–0.80; p < 0.001), respectively.
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Figure 2. Pleiotropic effects of EPA.
AA: Arachidonic acid; EPA: Eicosapentaenoic acid; hsCRP: High-sensitivity C-reactive protein; ICAM-1: Intercellular
adhesion molecule 1; IL: Interleukin; Lp-PLA2: Lipoprotein-associated phospholipase 2; MMPs: Matrix
metalloproteinases; NO: Nitric oxide; oxLDL: Oxidized low-density lipoprotein; RLP-C: Remnant lipoprotein
cholesterol.
Data taken from [47,50].
Pleiotropic effects of EPA
These data support the likelihood that IPE reduced risk of CVD events by mechanisms of EPA beyond TG
reduction. Although these mechanisms are not completely understood, they are likely multifactorial, including an
association with EPA levels post dosing with 4 g/day of IPE [9]. A recent evaluation of EPA levels and cardiovascular
outcomes in REDUCE-IT found that median serum EPA level in IPE-treated patients increased from 26.1 μg/l
at baseline to 158 μg/l at 5 years [74]. The difference in median percent change from baseline between the IPE and
placebo groups was 448.1% (p < 0.001). Achieved EPA levels in the IPE group correlated strongly (p < 0.001) with
the primary end point, the key secondary end point, cardiovascular death, MI, stroke, coronary revascularization,
unstable angina, sudden cardiac death, cardiac arrest, new heart failure and all-cause mortality [74]. In contrast,
changes in biomarker levels such as TGs, LDL-C and high-sensitivity C-reactive protein (hsCRP) had a limited
impact on reducing the relative risk of both the primary and secondary end points [74].
The pleiotropic effects of EPA have been reviewed extensively [46,47,50,51] and may include a reduction in
lipids, lipoproteins and inflammatory markers; preservation of cell membrane structure and normal distribution of
membrane cholesterol [47,51]; increased EPA content in the vessel wall [46,75]; increased circulating EPA/arachidonic
acid (AA) ratio (which may be indicative of cardiovascular benefit because high EPA:AA ratios are associated
with decreased proinflammatory and pro-aggregatory mediators, whereas low EPA:AA ratios are associated with
cardiovascular events including venous thromboembolisms, major adverse limb effects and increased mortality
in patients hospitalized for decompensated heart failure) [47,51,76,77]; and inhibited platelet aggregation [47,50]
(Figure 2). An analysis of two prior IPE Phase III clinical studies (Multi-center, Placebo-controlled, Randomized,
Double-blind, 12-week Study with an Open-label Extension [MARINE] and ANCHOR), found that, compared
with placebo, IPE 4 g/day significantly reduced lipoprotein-associated phospholipase A2 (Lp-PLA2) by 14 to 19%
and hsCRP by 22 to 36% (both p < 0.001) [78]. In addition, EPA is a precursor to specialized pro-resolving
mediators (RvE1; RvE2), both of which potently resolve inflammation [79,80]. Of interest, prespecified 9-month
interim results from the ongoing Effect of Vascepa on Improving Coronary Atherosclerosis in People with High
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Triglycerides Taking Statin Therapy (EVAPORATE) trial reported that, while there was no significant change in
the primary end point of low-attenuation plaque between IPE and placebo, after adjustment for baseline factors,
there was slowing of total non-calcified plaque, total plaque (noncalcified + calcified plaque), fibrous plaque and
calcified plaque for IPE versus placebo (all p ≤ 0.011) [81]. The final results of EVAPORATE are eagerly awaited.
Safety & additional considerations from REDUCE-IT
IPE was found to be well tolerated in REDUCE-IT, with no significant differences from placebo in the overall rate
of adverse events (AEs) or serious AEs (SAEs) leading to discontinuation. Specific AEs that were significantly more
common in the IPE group than in the placebo group are important to consider. The rate of serious adverse bleeding
events (e.g., gastrointestinal, CNS and other bleeding events) trended toward significance in the IPE versus placebo
group (2.7 vs 2.1%; p = 0.06). However, there were no fatal bleeding events attributable to the study drug in the
trial, and no difference between groups in rates of adjudicated hemorrhagic stroke (0.3 vs 0.2%; p = 0.55), serious
CNS bleeding (0.3 vs 0.2%; p = 0.42), or gastrointestinal bleeding (1.5 vs 1.1%; p = 0.15). Of note, the rate of
anemia was significantly lower for the IPE group compared with the placebo group (4.7 vs 5.8%; p = 0.03) [9].
The rate of peripheral edema was higher in the IPE group compared with the placebo group (6.5 vs 5.0%; p
= 0.002); however, there was no significant difference in the prespecified adjudicated tertiary end point of heart
failure between groups [9].
Of note, the rate of atrial fibrillation (AF) was higher in the IPE group compared with the placebo group (5.3 vs
3.9%; p = 0.003). Likewise, the rate of hospitalization for AF or atrial flutter, a prespecified adjudicated tertiary end
point, was higher for patients taking IPE compared with placebo (3.1 vs 2.1%; p = 0.004) [9]. However, most of the
AF and/or atrial flutter events observed with IPE in REDUCE-IT occurred in patients with a history of AF and/or
atrial flutter at baseline and were not considered serious [8]. Sequelae from AF/flutter such as stroke, MI, cardiac
arrest and sudden cardiac death occurred at significantly lower rates in the IPE group compared with placebo in the
overall trial. In addition, these arrhythmogenic events occurred at relatively low rates when considered in the context
of the observed benefits of treatment with IPE. The FDA examined AF risk-related data and determined that,
“given the strength and consistency of the finding of reduction of major adverse cardiovascular events in REDUCE-IT, the
benefit–risk assessment favors the use of Vascepa [IPE] for CVD risk reduction in the intended population with caution
regarding a potential increase in risk of AF” [82].
LDL-C and hsCRP increased from baseline in the placebo group by ∼10 and ∼30%, respectively, leading the
FDA and others to examine the possibility that the mineral oil placebo used in REDUCE-IT may have impacted
these parameters [82]. Exploratory analyses conducted by the FDA suggested that the observed difference in LDL-C
and hsCRP levels between the IPE and placebo groups could not account for the robust reduction in CVD event
risk [82]. Thus, it was considered unlikely that the mineral oil placebo clinically influenced overall study outcomes
in REDUCE-IT. Of interest, an analysis of coronary computed tomography angiography data from two different
randomized clinical trials (one using a mineral oil placebo, the other using a nonmineral oil placebo) concluded that
progression of plaque volumes was not related to consumption of mineral oil in the quantities used in these placebo
capsules [83]. In addition, a meta-analysis examined 21 randomized controlled trials which utilized an oral mineral
oil placebo, finding that increases in lipid parameters (LDL-C, HDL-C, TG and total cholesterol) with mineral oil
placebo were not significant [84]. However, significant LDL-C increases were observed in patient subgroups with
high-baseline statin use and in those with consumption of >4 g/day of mineral oil [84].
IPE’s FDA indications
The initial and continuing indication for IPE is as an adjunct to diet to reduce TG levels in adult patients with
severe (TG levels ≥500 mg/dl) hypertriglyceridemia [8]. Following an FDA advisory panel’s unanimous vote [85],
in December 2019, the FDA approved IPE for an additional indication based on the CVD event risk reduction
demonstrated in REDUCE-IT [86]. IPE is the first FDA-approved drug to reduce CVD event risk among patients
with elevated TG levels as an add-on to maximally tolerated statin therapy. As such it is important that we examine
and clarify/define key aspects of the new indication to ensure access to IPE in patients who would be appropriate
candidates for this treatment.
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Table 5. Weighted prevalence of TG ≥150 mg/dl among different subgroups of adults aged 20 and over in NHANES
2007–2014.
Population Prevalence of TG ≥150 mg/dl, % (Number/Total Population)
Overall 25.9 (56.9 M/219.9 M)
Statin-treated subgroup 31.6 (12.3 M/38.9 M)
Statin-treated + LDL-C 100 mg/dl subgroup 27.6 (6.0 M/21.7 M)
Statin-treated + DM subgroup 39.5 (4.9 M/12.4 M)
Statin-treated + ASCVD subgroup 30.5 (3.1 M/10.1 M)
Statin-treated + DM or ASCVD subgroup 34.4 (6.4 M/18.6 M)
ASCVD: Atherosclerotic cardiovascular disease; DM: Diabetes mellitus; LDL-C: Low-density lipoprotein cholesterol; M: Million; TG: Triglycerides.
Reproduced from [96] CC BY-NC 4.0
Newly expanded FDA indication for IPE
IPE is now approved in the US as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke,
coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated TG levels
(≥150 mg/dl) and established CVD or diabetes mellitus and two or more additional risk factors for CVD [8].
Maximally tolerated statin therapy
Maximally tolerated statin therapy is defined as the highest intensity and frequency of a statin that can be tolerated,
which, in the case of statin-intolerant patients, would be no statin [87]. Statin intolerance is generally defined as
unacceptable adverse effects or significant biomarker abnormalities that resolve with discontinuation of therapy
and recur with re-challenge of at least two different statins (preferably statins using different metabolic pathways),
with one of which prescribed at the lowest approved dose [87–89].
Lipid parameters
The expanded FDA indication for IPE does not specify any particular criteria for LDL-C; therefore, the choice
of IPE should not be influenced by a patient’s achieved LDL-C. In REDUCE-IT, patients treated with IPE had a
cardiovascular benefit regardless of baseline LDL-C levels [9]. The expanded indication specifies that patients should
have elevated TG levels (≥150 mg/dl), but, unlike the study criteria, does not specify any upper limit for TG
levels and does not require that the TG levels be obtained in the fasting state. REDUCE-IT included a number of
patients with TG levels >500 mg/dl; significant CVD event reduction was demonstrated by IPE versus placebo in
all TG subgroups [73]. Again, IPE demonstrated benefits on CVD event risk reduction, irrespective of baseline or
on-treatment TG levels.
At-risk population
In addition to being on maximally tolerated statin therapy and having TG levels ≥150 mg/dl, the at-risk population
eligible for IPE, as defined in the expanded indication, should have either established CVD or diabetes mellitus
with ≥2 additional risk factors for CVD. In REDUCE-IT, established CVD was described as a prior cardiovascular
event, such as ischemic stroke, MI, or cardiovascular revascularization, as well as coronary artery disease, peripheral
artery disease, carotid artery disease and/or cerebrovascular disease [8,90]. Of note, the expanded indication for IPE
does not specify a minimum or maximum age for adults. Diabetes mellitus encompasses both Type 1 and Type 2
diabetes. Finally, additional CVD risk factors or risk enhancers may include hypertension; smoking history; family
history of CVD [91]; older age (≥55 years in men; ≥65 years in women); hypercholesterolemia [92]; low HDL-C
levels (≤40 in men; ≤50 in women); hsCRP level >3.0 mg/l; body mass index >25 kg/m2 [93]; microalbuminuria;
renal dysfunction; chronic kidney disease; end-stage renal disease [94]; peripheral vascular disease; and physical
inactivity [8,90,95].
The size of the at-risk population can be estimated with available data. Based on an analysis of NHANES data
from 2007 to 2014, a projected 38.9 million patients in the US are on statin therapy; 31.6% (12.3 million) of these
statin-treated patients have TG levels ≥150 mg/dl, and 34.4% have established ASCVD or diabetes (Table 5) [96].
Of interest, approximately 6–12 million adult patients with a clinical indication for statin therapy may be statin-
intolerant and, among these patients, those with TG levels ≥150 mg/dl could potentially benefit from treatment
with IPE [97,98].
164 Future Cardiol. (2020) 17(1) future science group
Impact of icosapent ethyl expanded FDA indication Review
Cost–effectiveness of IPE
A report by the Institute for Clinical and Economic Review found that, based on findings from REDUCE-IT, IPE
versus optimal medical management results in a cost of $18,000 per quality-adjusted life-year (QALY) gained (well
below the historical cost–effectiveness threshold of $50,000 per QALY gained) [99]. Thus, IPE was considered ‘high
long-term value for money’ [99]. This cost/QALY decreased to $16,000 when revascularization and unstable angina
were included in the base model. From a health economics perspective IPE represents an optimal therapeutic, a
low-cost, effective treatment for a highly prevalent disorder.
Preliminary findings from a cost–effectiveness analysis that combined patient-level in-trial cost and clinical
outcomes and long-term costs, events and life expectancy derived from Markov simulation models were presented
at the 2019 AHA meeting [100]. Using treatment effects from REDUCE-IT, national healthcare costs and estimated
net costs for IPE of $4.16/day, the QALYs for IPE and control were 3.34 and 3.27, respectively. Mean costs in
the trial were $27,576 and $28,205, respectively, demonstrating improved healthcare outcomes at lower healthcare
costs. IPE was found to be cost saving in 70% of simulations. In addition, IPE was not only cost-effective in
the treatment of patients at high risk for CVD, but also was projected to reduce long-term healthcare costs
over patients’ lifetimes [100]. A subsequent patient-level cost-effectiveness analysis that focused on US participants
from REDUCE-IT found that the probability of IPE being cost-effective at thresholds of $50,000, $100,000 and
$150,000 per QALY gained was demonstrated in >99% of simulations [101]. In primary prevention, the incremental
cost-effectiveness ratio was $36,118 per QALY gained, and the probability of IPE being cost-effective was shown
in 62.3, 79.1 and 83.5% of simulations at thresholds of $50,000, $100,000 and $150,000 per QALY gained,
respectively. In secondary prevention, IPE was dominant in 98.6% of simulations, with the probability of being
cost-effective shown in 100% of simulations for each of the per-QALY-gained thresholds.
Thus, these cost–effectiveness analysis findings for IPE, along with the clinical efficacy and safety data from
REDUCE-IT, suggest that IPE is an inexpensive, safe and effective therapy that lowers CVD risk for a large
high-risk population.
Discussion & conclusion
Hypertriglyceridemia is associated with increased ASCVD risk, independent of LDL-C control [6]. Statin-treated
patients may have persistent cardiovascular risk despite achieving optimal levels of LDL-C with statins, with
or without other LDL-C–lowering treatments; in fact, among statin-treated patients, up to 70% of residual
risk persists in multiple placebo-controlled studies [102–106]. However, outcomes trials in which residual risk was
targeted by addition of TG-lowering treatments such as fibrates and niacin to statins did not show ASCVD risk
reduction [32,33,38]. Similarly, trials of mixed omega-3 fatty acids have generally failed to demonstrate ASCVD risk
reduction among patients with varying levels of baseline statin use [56–61].
By contrast, REDUCE-IT demonstrated that addition of IPE to statin treatment in patients with high TG and
controlled LDL-C reduced important first ASCVD events by 25% [9] and, among the US cohort of 3146 patients,
reduced total ASCVD events by 30% [72]. Following the positive findings from REDUCE-IT, the FDA approved
an expanded indication for IPE as an adjunct to maximally tolerated statin therapy to reduce the risk of MI,
stroke, coronary revascularization and unstable angina requiring hospitalization in adults with elevated TG levels
(≥150 mg/dl) and established CVD or diabetes mellitus and two or more additional risk factors for CVD [8]. This
new indication enables use of IPE to reduce the risk of ASCVD events for a large at-risk population. Results of
recent cost analyses incorporating REDUCE-IT findings support that IPE is a cost-effective option for ASCVD
residual risk reduction [99,100].
Other large CV outcomes trials of TG-lowering treatments in statin-treated patients with hypertriglyceridemia
have not yet shown encouraging results. The STRENGTH trial, designed to investigate whether addition of
4 g/day of an EPA + DHA mixture to statin treatment in high-risk adults with hypertriglyceridemia would reduce
CVD events, was recently discontinued early as the EPA + DHA combination was unlikely to demonstrate a
benefit to patients [67–69]. Detailed findings of the STRENGTH trial have not yet been published. The ongoing
PROMINENT trial will clarify whether addition of pemafibrate to statin treatment in patients with type 2 diabetes
and elevated TG can reduce CVD event risk [43].
IPE represents the first TG-lowering treatment option that effectively lowers residual CVD risk. Of note, IPE
demonstrated significant ASCVD event reduction in REDUCE-IT, independent of TG levels. Thus, it is likely
that multifactorial pleiotropic mechanisms of IPE, beyond TG lowering, contributed to ASCVD risk reduction.
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The expanded FDA indication will allow a larger at-risk population access to this cost-effective treatment for CVD
event prevention.
Future perspective
The REDUCE-IT results demonstrate an important adjunctive approach to reducing residual CV risk beyond
LDL-C reduction with a statin. IPE reduced all major CV end points, including CV mortality over and above those
observed with a statin in patients with well-controlled LDL-C levels [9]. These benefits were observed independent
of baseline or attained TG levels [73]. This suggests that the benefits observed with IPE were largely attributed
to changes in EPA levels, as opposed to changes in lipid biomarker levels [74]. Much more work will have to be
performed to more fully ascertain the mechanistic basis for these benefits, as it is likely that IPE acts through a
variety of pleiotropic effects.
Atherosclerosis is a chronic inflammatory disease [107]. It is established that EPA is a parent molecule for
downstream E series resolvins (RvE1, RvE2, RvE3), which are specialized molecules that resolve inflammation [108].
RvE1 has been found to attenuate LTB4-induced proinflammatory signaling and polymorphonuclear leukocyte
migration, and RvE3 has shown potent inhibitory action on neutrophil chemotaxis [79,109]. RvE2 has demonstrated
upregulating effects on macrophage phagocytosis and IL-10 production [80]. Consistent with this, EPA has been
shown to: reduce circulating levels of pro-inflammatory eicosanoids (prostaglandins and leukotrienes) as well as IL-
1β and TNF-α [110–116]; reduce inflammation by inhibiting endothelial cell adhesion molecule expression (ICAM-1,
VCAM-1) which reduces the binding and transmigration of monocytes and T helper cells, thereby preventing their
entry into the subendothelial space, an early event in atherogenesis [117–120]; inhibit the translocation of transcription
regulator nuclear factor-κB (NF-κB) into the nucleus and the activation of inflammation pathways [75,121]; suppress
the expression of pro-inflammatory cytokines by T helper cells and stimulate production of IL-10, a potent anti-
inflammatory cytokine [122,123]; and inhibit activation of the nucleotide-binding oligomerization domain, leucine-
rich–containing receptor family pyrin domain-containing 3 (NLRP3) inflammasome [124,125]. The remarkable
findings of a 48% relative risk reduction in cardiac arrest and a 31% relative risk reduction in sudden cardiac death
in the REDUCE-IT treatment group suggest that EPA may exert anti-arrhythmogenic influences on the ventricles,
an issue that warrants intensive further investigation [9].
It is anticipated that the clinical benefits of IPE will likely extend into other areas of medicine. EPA has
bacteriostatic and bactericidal properties in vitro and is being studied as an anti-infective agent [126–129]. Because of
its anti-inflammatory effects, EPA is being evaluated as a potential means by which to resolve tissue damage following
normal inflammatory responses to infection [124,130]. EPA may also play a role in inhibiting the development of
cytokine storm syndrome in patients who are septic or infected with influenza or COVID-19 (severe acute
respiratory syndrome coronavirus 2 [SARS-CoV-2]) based on evidence suggesting that unsaturated fatty acids
inactivate enveloped viruses, enhancing recovery from these infections [131]. Pilot trials of EPA (NCT04335032,
NCT04323228) and specifically IPE (NCT04412018) in patients with COVID-19 are in early stages. Due to its
ability to control inflammation and modulate the composition of the gut microbiome, EPA is being used in clinical
trials to ascertain its impact on inflammatory bowel diseases and risk for colon polyps and cancer [124,132,133]. EPA’s
potential role in reducing the risk of cognitive defects such as Alzheimer’s disease and vascular dementia [134,135]
and depression [136,137] has also been previously studied. Given its tolerability and low potential for toxicity, the
potential therapeutic efficacy of IPE across such a broad clinical spectrum of disease has aroused considerable
interest. The results of randomized clinical trials are eagerly awaited.
Executive summary
Hypertriglyceridemia
• Hypertriglyceridemia is associated with increased cardiovascular disease (CVD) risk, independent of low-density
lipoprotein cholesterol (LDL-C) control.
• Among adults in the USA aged ≥45 years, the additional annual cost burden of having triglyceride (TG) levels
≥150 mg/dl compared with <150 mg/dl is estimated to be over $10 billion.
TG-lowering drugs & cardiovascular outcomes
• Niacin, fibrates and mixed (eicosapentaenoic acid [EPA] + docosahexaenoic acid [DHA]) omega-3 fatty acids have
TG-lowering effects; however, large outcomes trials evaluating these treatments as add-on therapy to statins
have failed to demonstrate reductions in CVD events.
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• An open-label clinical trial of the omega-3 fatty acid EPA alone demonstrated that in Japanese patients,
moderate-dose EPA (1.8 g daily) in addition to low-dose statin treatment significantly reduced ASCVD events by
19% compared with the statin-only control (p = 0.011).
Overview of REDUCE-IT
• The randomized, controlled Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
(REDUCE-IT) found that in statin-treated patients with elevated TG levels and high risk for CVD, addition of
icosapent ethyl (IPE), a highly purified, stable ethyl ester of EPA (4 g/day), significantly reduced the occurrence of
CVD events (cardiovascular death, nonfatal myocardial infarction [MI], nonfatal stroke, coronary
revascularization, or unstable angina) by 25% compared with control (statin plus placebo) (p < 0.0001).
• The significant reduction in both the primary and key secondary CVD efficacy end points by IPE as add-on therapy
to statin compared with placebo in REDUCE-IT was independent of both baseline and achieved TG levels,
suggesting that additional pleiotropic mechanisms of EPA contributed to the CVD risk reduction.
IPE’s expanded US FDA indication
• Based on REDUCE-IT findings, IPE now has an expanded indication in the US as an adjunct to maximally tolerated
statin therapy to reduce the risk of MI, stroke, coronary revascularization and unstable angina requiring
hospitalization in adult patients with elevated TG levels (≥150 mg/dl) and either established CVD or diabetes
mellitus plus two or more additional risk factors for CVD.
• Important points of clarification related to this expanded indication include that maximally tolerated statin
therapy is considered the highest tolerated intensity and frequency of a statin, which for statin-intolerant
patients would be no statin. There is no requirement for any particular target LDL-C level being attained prior to
consideration of IPE therapy for patients with TG levels ≥150 mg/dl (either fasting or non-fasting) and a high risk
for CVD events.
At-risk population
• Approximately 12 million statin-treated patients in the US have TG levels ≥150 mg/dl, of whom approximately
50% have established ASCVD or diabetes.
• An estimated ∼4 million adults may be statin intolerant and, among these patients, those with TG levels
≥150 mg/dl and high CVD risk could potentially benefit from treatment with IPE.
Cost–effectiveness of IPE
• An analysis by the Institute for Clinical and Economic Review based on REDUCE-IT data found IPE resulted in a
cost of $18,000 per quality-adjusted life-year (QALY) gained versus optimal medical management – well below
the most conservative cost–effectiveness threshold of $50,000/QALY gained.
• Patient-level cost–effectiveness analyses based on REDUCE-IT data report that IPE improves healthcare outcomes
at lower healthcare costs than placebo, and, among US participants, is cost-effective at $50,000, $100,000, and
$150,000 per-QALY-gained thresholds.
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